The small molecule inhibitor NAV-2729 has a complex target profile including multiple ADP-ribosylation factor regulatory proteins
Journal of Biological Chemistry · 2023
DOI: 10.1016/j.jbc.2023.102992 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023. Verfasst von Eric M Rosenberg und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: ADP-Ribosylation Factors, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intramural NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
The ADP-ribosylation factor (Arf) GTPases and their regulatory proteins are implicated in cancer progression. NAV-2729 was previously identified as a specific inhibitor of Arf6 that reduced progression of uveal melanoma in an orthotopic xenograft. Here, our goal was to assess the inhibitory effects of NAV-2729 on the proliferation of additional cell types. We found NAV-2729 inhibited proliferation of multiple cell lines, but Arf6 expression did not correlate with NAV-2729 sensitivity, and knockdown of Arf6 affected neither cell viability nor sensitivity to NAV-2729. Furthermore, binding to native Arf6 was not detected; however, we determined that NAV-2729 inhibited both Arf exchange factors and Arf GTPase-activating proteins. ASAP1, a GTPase-activating protein linked to cancer progression, was further investigated. We demonstrated that NAV-2729 bound to the PH domain of ASAP1 and changed ASAP1 cellular distribution. However, ASAP1 knockdown did not fully recapitulate the cytoskeletal effects of NAV-2729 nor affect cell proliferation. Finally, our screens identified 48 other possible targets of NAV-2729. These results illustrate the complexities of defining targets of small molecules and identify NAV-2729 as a model PH domain-binding inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
- Center for Structural Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
- Department of Biology, Williams College, Williamstown, Massachusetts, USA.
- Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA; Laboratory of Cell and Developmental Signaling, Center for Cancer Research, Frederick, Maryland, USA.
- Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA. Electronic address: randazzp@mail.nih.gov.
Förderung
- Intramural NIH HHS
- National Institutes of Health
Zitieren
APA
Rosenberg, E. M., Jian, X., Soubias, O., Yoon, H. Y., Yadav, M. P., Hammoudeh, S., Pallikkuth, S., Akpan, I., Chen, P. W., Maity, T. K., Jenkins, L. M., Yohe, M. E., Byrd, R. A., & Randazzo, P. A. (2023). The small molecule inhibitor NAV-2729 has a complex target profile including multiple ADP-ribosylation factor regulatory proteins. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.102992
Vancouver
Rosenberg EM, Jian X, Soubias O, Yoon HY, Yadav MP, Hammoudeh S, et al. The small molecule inhibitor NAV-2729 has a complex target profile including multiple ADP-ribosylation factor regulatory proteins. Journal of Biological Chemistry. 2023. doi:10.1016/j.jbc.2023.102992
BibTeX
@article{Rosenberg2023,
author = {Rosenberg, Eric M and Jian, Xiaoying and Soubias, Olivier and Yoon, Hye-Young and Yadav, Mukesh P and Hammoudeh, Sarah and Pallikkuth, Sandeep and Akpan, Itoro and Chen, Pei-Wen and Maity, Tapan K and Jenkins, Lisa M and Yohe, Marielle E and Byrd, R Andrew and Randazzo, Paul A},
title = {The small molecule inhibitor NAV-2729 has a complex target profile including multiple ADP-ribosylation factor regulatory proteins},
journal = {Journal of Biological Chemistry},
year = {2023},
doi = {10.1016/j.jbc.2023.102992}
}
EUVIMED